Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorLAVOUE, V.
dc.contributor.authorHUCHON, C.
dc.contributor.authorAKLADIOS, C.
dc.contributor.authorALFONSI, P.
dc.contributor.authorBAKRIN, N.
dc.contributor.authorBALLESTER, M.
dc.contributor.authorBENDIFALLAH, S.
dc.contributor.authorBOLZE, P. A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorBOURGIN, C.
dc.contributor.authorCHABBERT-BUFFET, N.
dc.contributor.authorCOLLINET, P.
dc.contributor.authorCOURBIERE, B.
dc.contributor.authorDE LA MOTTE ROUGE, T.
dc.contributor.authorDEVOUASSOUX-SHISHEBORAN, M.
dc.contributor.authorFALANDRY, C.
dc.contributor.authorFERRON, G.
dc.contributor.authorFOURNIER, L.
dc.contributor.authorGLADIEFF, L.
dc.contributor.authorGOLFIER, F.
dc.contributor.authorGOUY, S.
dc.contributor.authorGUYON, F.
dc.contributor.authorLAMBAUDIE, E.
dc.contributor.authorLEARY, A.
dc.contributor.authorLECURU, F.
dc.contributor.authorLEFRERE-BELDA, M. A.
dc.contributor.authorLEBLANC, E.
dc.contributor.authorLEMOINE, A.
dc.contributor.authorNARDUCCI, F.
dc.contributor.authorOULDAMER, L.
dc.contributor.authorPAUTIER, P.
dc.contributor.authorPLANCHAMP, F.
dc.contributor.authorPOUGET, N.
dc.contributor.authorRAY-COQUARD, I.
dc.contributor.authorROUSSET-JABLONSKI, C.
dc.contributor.authorSENECHAL-DAVIN, C.
dc.contributor.authorTOUBOUL, C.
dc.contributor.authorTHOMASSIN-NAGGARA, I.
dc.contributor.authorUZAN, C.
dc.contributor.authorYOU, B.
dc.contributor.authorDARAI, E.
dc.date.accessioned2020-06-26T09:46:02Z
dc.date.available2020-06-26T09:46:02Z
dc.date.issued2019-06
dc.identifier.issn2468-7847 (Electronic) 2468-7847 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/8221
dc.description.abstractEnAdjuvant chemotherapy by carboplatin and paclitaxel is recommended for all high-grade ovarian and tubal cancers (FIGO stages I-IIA) (grade A). After primary surgery is complete, 6 cycles of intravenous chemotherapy (grade A) are recommended, or a discussion with the patient about intraperitoneal chemotherapy, according to her risk-benefit ratio. After complete interval surgery for FIGO stage III, hyperthermic intraperitoneal chemotherapy (HIPEC) can be proposed, in accordance with the modalities of the OV-HIPEC trial (grade B). In cases of postoperative tumor residue or in FIGO stage IV tumors, chemotherapy associated with bevacizumab is recommended (grade A).
dc.language.isoENen_US
dc.subject.enMORPH3Eus
dc.title.enManagement of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up)
dc.title.alternativeJ Gynecol Obstet Hum Reproden_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.jogoh.2019.03.018en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30936025en_US
bordeaux.journalJournal of gynecology obstetrics and human reproductionen_US
bordeaux.page379-386en_US
bordeaux.volume48en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20gynecology%20obstetrics%20and%20human%20reproduction&rft.date=2019-06&rft.volume=48&rft.issue=6&rft.spage=379-386&rft.epage=379-386&rft.eissn=2468-7847%20(Electronic)%202468-7847%20(Linking)&rft.issn=2468-7847%20(Electronic)%202468-7847%20(Linking)&rft.au=LAVOUE,%20V.&HUCHON,%20C.&AKLADIOS,%20C.&ALFONSI,%20P.&BAKRIN,%20N.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée